Article Content

Overall cancer death rates in the U.S. dropped continuously from 1991 through 2018 for a total decrease of 31 percent, including a 2.4 percent decline from 2017 to 2018. The news comes from the American Cancer Society's annual Cancer Statistics, 2021 article, appearing in CA: A Cancer Journal for Clinicians (doi: 10.3322/caac.21654). This year marks the American Cancer Society's 70th anniversary of reporting this data to inform the nation's fight against cancer.

cancer mortality. ca... - Click to enlarge in new windowcancer mortality. cancer mortality

The report estimates that in the U.S. in 2021, almost 1.9 million (1,898,160) new cancer cases will be diagnosed and 608,570 Americans will die from cancer. These projections are based on currently available incidence and mortality data through 2017 and 2018, respectively, and thus do not account for the impact of the COVID-19 pandemic on cancer diagnoses or deaths.


"The impact of COVID-19 on cancer diagnoses and outcomes at the population level will be unknown for several years because of the time necessary for data collection, compilation, quality control, and dissemination," said Rebecca Siegel, MPH, Scientific Director of Surveillance Research at the American Cancer Society and lead author of the report. "We anticipate that disruptions in access to cancer care in 2020 will lead to downstream increases in advanced stage diagnoses that may impede progress in reducing cancer mortality rates in the years to come."


Progress in reducing mortality has slowed for other leading causes of death in the U.S., but accelerated for cancer, which is the second-leading cause. An estimated 3.2 million cancer deaths have been averted from 1991 through 2018 due to reductions in smoking, earlier detection, and improvements in treatment, which are reflected in long-term declines in mortality for the four leading cancers: lung, breast, colorectal, and prostate.


Lung cancer is the most common cause of cancer death, accounting for more deaths than breast, prostate, and colorectal cancers combined. Sluggish progress against these latter cancers in recent years contrasts with accelerating reductions in the death rate for lung cancer, from 2.4 percent annually during 2009 to 2013 to 5 percent annually during 2014 to 2018. As a result, lung cancer accounted for almost half (46%) of the overall decline in cancer mortality in the past 5 years and spurred a record single-year drop (2.4% from 2017 to 2018) for the second year in a row.


Recent rapid reductions in lung cancer mortality reflect better treatment for the most common subtype-non-small cell lung cancer (NSCLC). Two-year relative survival for NSCLC has increased from 34 percent for patients diagnosed during 2009 through 2010 to 42 percent for those diagnosed during 2015 through 2016, including absolute gains of 5-6 percent for every stage of diagnosis. Two-year survival for small cell lung cancer remained at 14-15 percent during this time period.


Cervical cancer is almost 100 percent preventable through screening and, in recent years, the HPV vaccine, but continues to cause thousands of deaths in the U.S. annually. Approximately 11 women per day died from cervical cancer in 2018, half of whom were in their 50s or younger. It is the second-leading cause of cancer death among women in their 20s and 30s. Although the HPV vaccine holds promise to nearly eliminate cervical cancer with complete population coverage, U.S. vaccination rates remain far below those in other high-income countries: 57 percent of U.S. adolescent females are up-to-date versus >80 percent in Australia and >90 percent in the U.K. Per ACS guidelines HPV vaccinations are recommended in children starting between the ages of 9-12, and cervical cancer testing in young women should begin at age 25.


Top Statistics

Other highlights from Cancer Statistics 2021 include the following:


* Cancer is the leading cause of death in Hispanic, Asian American, and Alaska Native persons.


* The 5-year survival rate for all cancers combined diagnosed during 2010 through 2016 was 68 percent in White patients versus 63 percent in Black patients.


* For all stages combined, survival is the highest for prostate cancer (98%), melanoma of the skin (93%), and female breast cancer (90%), and lowest for cancers of the pancreas (10%), liver (20%), esophagus (20%), and lung (21%).


* Survival rates are lower for Black patients than for White patients for every cancer type except pancreas.


* Prostate, lung and bronchus, and colorectal cancers account for 46 percent of all incident cases in men, with prostate cancer alone accounting for 26 percent of diagnoses.


* For women, breast, lung, and colorectal cancers account for 50 percent of all new diagnoses, with breast cancer alone accounting for 30 percent of female cancers.


* In contrast to declining trends for lung and colorectal cancers, female breast cancer incidence rates increased by about 0.5 percent per year from 2008 to 2017, which is attributed at least in part to continued declines in the fertility rate and increased body weight.


* Colorectal cancer overtook leukemia in 2018 as the second-leading cause of cancer death in men aged 20-39 years, reflecting increasing trends in colorectal cancer in this age group, coinciding with declining rates for leukemia.


* The Black-White disparity in overall cancer mortality among men and women combined has declined from a peak of 33 percent in 1993 (279 vs. 211 per 100,000, respectively) to 13 percent in 2018 (174 vs. 154).


* Geographic disparities are widest for the most preventable cancers, such as lung and cervical cancers, for which incidence and mortality rates vary up to 5- and 3-fold, respectively, across states.



"While recent advances in treatment for lung cancer and several other cancers are reason to celebrate, it is concerning to see the persistent racial, socioeconomic, and geographic disparities for highly preventable cancers," said William G. Cance, MD, Chief Medical and Scientific Officer, American Cancer Society. "There is a continued need for increased investment in equitable cancer control interventions and clinical research to create more advanced treatment options to help accelerate progress in the fight against cancer."